The FDA has accepted a new drug application for neffy, a nasal spray designed to treat type I allergic reactions without an injection in adults and children who weigh 30 kg or more, according to an ARS Pharmaceuticals press release.
FDA approval would make neffy (ARS-1, ARS Pharmaceuticals) the first noninjectable treatment available to patients with type I allergic reactions, such as anaphylaxis, according to the release.
“The FDA acceptance of our NDA for neffy is a major milestone in our efforts to bring to patients the ability to deliver epinephrine with comparable pharmacokinetics to